Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease.
We describe a neonate with ductal-dependent congenital heart disease on extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, who required markedly high doses of prostaglandin E1 (PGE1) to maintain patency of the ductus arteriosus: The effects of ECMO on the pharmacokinetics of PGE1 are discussed.
Stone
D M
DM
Division of Cardiology, Carman Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Wayne State University, 3901 Beaubien, Detroit, MI 48201, USA. dstone@dmc.org
Frattarelli
D A C
DA
Karthikeyan
S
S
Johnson
Y R
YR
Chintala
K
K
D000527:Alprostadil / Q000008:administration & dosage* / Q000378:metabolism; D004374:Ductus Arteriosus, Patent / Q000000981:diagnostic imaging; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006330:Heart Defects, Congenital / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000151:congenital / Q000628:therapy; D007231:Infant, Newborn; D008471:Meconium Aspiration Syndrome / Q000628:therapy; D011666:Pulmonary Valve Stenosis / Q000628:therapy*; D014463:Ultrasonography; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000378:metabolism
D014665:Vasodilator Agents; D000527:Alprostadil